기업
GenScript ProBio signs MOU with GeneCraft to CMC of AAV gene therapies
by Yoonseok Suh
Development and production MOU for the IND of ‘RX001’, a candidate substance for AAV gene therapy
▲Left: Prof. Suk Chul Bae, CEO of GeneCraft, Right: Dr. Brian H. Min CEO of GenScript ProBio
GenScript ProBio, a global CDMO, and GeneCraft, a global research team led by Professor Suk Chul Bae of lung cancer mechanism research, announced that they had entered into a strategic partnership MOU concerning the development and production of a new drugs needed for ‘RX001’.
GenScript ProBio and GeneCraft have agreed to strengthen their cooperation in the AAV gene therapy field through this MOU.
GenScript ProBio and GeneCraft are in the process of signing a contract for plasmid and AAV development and production for the GeneCraft's own new drug candidate Pan-KRAS non-small cell lung cancer anti-cancer gene therapy (RX001) developed as a new drug.
With this agreement, GenScript ProBio has become a global partner that can support GeneCraft’s various gene therapy pipelines.
Brian H. Min, CEO of GenScript ProBio said, "We are very happy to cooperate with GeneCraft in strategic partnership, and we are looking forward to accelerating the development of GeneCraft’s gene therapy pipelines as a global partner through our accumulated technology”
Suk Chul Bae, CEO of GeneCraft said, “Through this strategic partnership with GeneScript ProBio, we look forward to successfully conducting the upcoming clinical trials of RX001, a first-in-class anticancer gene therapy. By establishing a long-term partnership we hope to become the global leaders in the gene therapy market”
